BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ansofaxine hydrochloride readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ansofaxine hydrochloride\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06426485-842@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ansofaxine hydrochloride: Phase 4 readout est. (NCT06426485)
DESCRIPTION:Ansofaxine hydrochloride\, phase 4\, Major Depressive Disorder.
 \nStudy: To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxin
 e Hydrochloride Sustained-release Tablets\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anso
 faxine-hydrochloride#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06426485
URL:https://assetmemo.bio/drug/ansofaxine-hydrochloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208357-842@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ansofaxine hydrochloride: Phase na readout est. (NCT07208357)
DESCRIPTION:Ansofaxine hydrochloride\, phase na.\nStudy: The Efficacy and S
 afety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibr
 omyalgia\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ansofaxine-hydrochloride#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07208357
URL:https://assetmemo.bio/drug/ansofaxine-hydrochloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709416-842@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ansofaxine hydrochloride: Phase na readout est. (NCT07709416)
DESCRIPTION:Ansofaxine hydrochloride\, phase na.\nStudy: Toludesvenlafaxine
  for Non-specific Low Back Pain\nEstimated primary completion: 1 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ansofaxine-hyd
 rochloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07709416
URL:https://assetmemo.bio/drug/ansofaxine-hydrochloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
